Catalog No.: PC-20715Not For Human Use, Lab Use Only.
Ifetroban sodium (BMS-180291, CPI211) is a potent and highly selective antagonist of thromboxane A2/prostaglandin endoperoxide (TP) receptors, inhibits platelet aggregation induced by arachidonate (800 uM) and U-46,619 (10 uM) with IC50 of 7 and 21 nM, respectively.
Ifetroban sodium (BMS-180291, CPI211) is a potent and highly selective antagonist of thromboxane A2/prostaglandin endoperoxide (TP) receptors, inhibits platelet aggregation induced by arachidonate (800 uM) and U-46,619 (10 uM) with IC50 of 7 and 21 nM, respectively.
BMS 180,291 antagonized U-46,619-induced platelet shape change competitively with a KB of 11 nM.
BMS 180,291 did not inhibit platelet aggregation induced by high concentrations of ADP (20 microM) or human alpha-thrombin (1 U/ml) at 1 uM. BMS 180,291 antagonized U-46,619-induced concentrations of rat aortae with a KB of 0.6 nM.
Ifetroban sodium (BMS-180291, CPI211) potently blocked spontaneous metastasis from primary tumors, without affecting tumor cell proliferation, motility, or tumor growth.
